The subjective experience of acute, experimentally-induced Salvia divinorum inebriation

Journal of Psychopharmacology

Volumn 29, Issue 4, 2015, Pages 426-435

  Addy, Peter H ^a,b   Garcia Romeu, Albert ^c   Metzger, Matthew ^d   Wade, Jenny ^e  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Goodwill Wellness Center   (United States)

^e UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Consciousness; hallucinogens; kappa; neuropharmacology; opioid; pharmacology; psychedelics; qualitative research; receptors; Salvia divinorum; salvinorin A

Indexed keywords

HERBACEOUS AGENT; PLACEBO; PSYCHEDELIC AGENT;

ADULT; AFFECT; ARTICLE; AWARENESS; COGNITIVE DEFECT; COMBUSTION; CONTENT ANALYSIS; CONTROLLED STUDY; DELUSION; DRUG ABUSE; FEMALE; HALLUCINOGEN RATING SCALE; HUMAN; HUMAN EXPERIMENT; INHALATION; INTOXICATION; MALE; NORMAL HUMAN; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SALVIA DIVINORUM; SENSORY STIMULATION; THEMATIC ANALYSIS; AGED; CHEMISTRY; COGNITION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; SALVIA; SUBSTANCE-RELATED DISORDERS;

ADMINISTRATION, INHALATION; ADULT; AGED; COGNITION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; SALVIA; SUBSTANCE-RELATED DISORDERS;

EID: 84924966123     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115570081     Document Type: Article

References (75)

1. Addy PH. Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology (Berl). 2012 ; 220: 195-204
2. Albertson DN, Grubbs LE. Subjective effects of Salvia divinorum: LSD- or marijuana-like?. J Psychoactive Drugs. 2009 ; 41: 213-217
3. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Publishing ; 2013 :
4. Baggott MJ, Erowid E, Erowid F, et al. Use patterns and self-reported effects of Salvia divinorum: An internet-based survey. Drug Alcohol Depend. 2010 ; 111: 250-256
5. Baker AK, Meert TF. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. J Pharmacol Exp Ther. 2002 ; 302: 1253-1264
6. Barbanoj MJ, Riba J, Clos S, et al. Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl). 2008 ; 196: 315-326
7. Beauregard M, Paquette V. Neural correlates of a mystical experience in Carmelite nuns. Neurosci Lett. 2006 ; 405: 186-190
8. Blom J, Sommer I Hallucinations: Research and Practice. Blom J Sommer I, ed. Chicago: Springer ; 2012: 157-169.
9. Braida D, Limonta V, Capurro V, et al. Involvement of kappa-opioid and endocannabinoid system on salvinorin A-induced reward. Biol Psychiatry. 2008 ; 63: 286-292
10. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006 ; 3: 77-101
11. Brogaard B. Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia. Front Hum Neurosci. 2013 ; 7: 657
12. Bucheler R, Gleiter CH, Schwoerer P, et al. Use of nonprohibited hallucinogenic plants: Increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviners Sage). Pharmacopsychiatry. 2005 ; 38: 1-5
13. Buda M, Fornito A, Bergstrom ZM, et al. A specific brain structural basis for individual differences in reality monitoring. J Neurosci. 2011 ; 31: 14308-14313
14. Butelman ER, Rus S, Prisinzano TE, et al. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: Dissociation from classic hallucinogen effects. Psychopharmacology (Berl). 2010 ; 210: 253-262
15. Butelman ER, Yuferov V, Kreek MJ. Kappa-opioid receptor/dynorphin system: Genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 2012 ; 35: 587-596
16. Casselman I, Heinrich M.. Novel use patterns of Salvia divinorum: Unobtrusive observation using YouTube. J Ethnopharmacol. 2011 ; 138: 662-667
17. CoyleJRPrestiDEBaggottMJ (2012) Quantitative analysis of narrative reports of psychedelic drugs. Available at: http://arxiv.org/abs/1206.0312.
18. Craig AD. How do you feel - now? The anterior insula and human awareness. Nat Rev Neurosci. 2009 ; 10: 59-70
19. Crick FC, Koch C. What is the function of the claustrum?. Philos Trans R Soc Lond B Biol Sci. 2005 ; 360: 1271-1279
20. DePaoli AM, Hurley KM, Yasada K, et al. Distribution of kappa opioid receptor mRNA in adult mouse brain: An in situ hybridization histochemistry study. Mol Cell Neurosci. 1994 ; 5: 327-335
21. Dos Santos RG, Grasa E, Valle M, et al. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl). 2012 ; 219: 1039-1053
22. 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Center for Behavioral Health Statistics and Quality, SAMHSA ; 2013 :
23. Drug Enforcement Administration (2012) Salvia divinorum and salvinorin A. Available at: http://www.deadiversion.usdoj.gov/drug-chem-info/salvia-d.pdf (accessed 28 January 2015).
24. Freeman KB, Naylor JE, Prisinzano TE, et al. Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl). 2014 ; 231: 2751-2758
25. Gonzalez D, Riba J, Bouso JC, et al. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend. 2006 ; 85: 157-162
26. Gorecki H Symphony No. 3. Tampa, FL: Nonesuch Records ; 1976 :
27. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006 ; 187: 268 284-283 292
28. Hanes KR. Antidepressant effects of the herb Salvia divinorum: A case report. J Clin Psychopharmacol. 2001 ; 21: 634-635
29. Hanes KR. Salvia divinorum: Clinical and research potential. MAPS Bulletin. 2003 ; 13: 18-20
30. Izenwasser S, Staley JK, Cohn S, et al. Characterization of kappa1-opioid receptor binding in human insular cortex. Life Sci. 1999 ; 65: 857-862
31. Jenks AA, Walker JB, Kim SC. Evolution and origins of the Mazatec hallucinogenic sage, Salvia divinorum (Lamiaceae): A molecular phylogenetic approach. J Plant Res. 2011 ; 124: 593-600
32. Johnson M, Richards W, Griffiths R. Human hallucinogen research: Guidelines for safety. J Psychopharmacol. 2008 ; 22: 603-620
33. Johnson MW, MacLean KA, Reissig CJ, et al. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 2011 ; 115: 150-155
34. Johnston LD, O'Malley PM, Bachman JG, et al Monitoring the Future National Survey Results On Drug Use, 1975-2012. Volume I: Secondary School Students. Ann Arbor: Institute for Social Research, The University of Michigan ; 2013 :
35. Kelly BC. Legally tripping: A qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs. 2011 ; 43: 46-54
36. Khey DN, Miller BL, Griffin OH. Salvia divinorum use among a college student sample. J Drug Educ. 2008 ; 38: 297-306
37. Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J Subst Abuse Treat. 2002 ; 23: 273-283
38. Lange JE, Daniel J, Homer K, et al. Salvia divinorum: Effects and use among YouTube users. Drug Alcohol Depend. 2010 ; 108: 138-140
39. Luke D, Terhune D. The induction of synaesthesia with chemical agents: A systematic review. Frontiers in Psychology. 2013 ; 4 :
40. MacLean KA, Johnson MW, Reissig CJ, et al. Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl). 2013 ; 226: 381-392
41. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain. 1998 ; 121: 1819-1840
42. Mansour A, Fox CA, Akil H, et al. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci. 1995 ; 18: 22-29
43. Mathur BN. The claustrum in review. Front Syst Neurosci. 2014 ; 8: 48
44. Mendelson JE, Coyle JR, Lopez JC, et al. Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: A placebo-controlled trial. Psychopharmacology (Berl). 2011 ; 214: 933-939
45. Mocellin R, Walterfang M, Velakoulis D. Neuropsychiatry of complex visual hallucinations. Aust N Z J Psychiatry. 2006 ; 40: 742-751
46. Morani AS, Kivell B, Prisinzano TE, et al. Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav. 2009 ; 94: 244-249
47. NygårdEA (2007) Listening to the sage: The experience of learning from the Salvia divinorum altered state. PhD Thesis, Institute of Transpersonal Psychology, Palo Alto, CA.
48. PaterlineBAAlboMJ (2013) A content analysis of Salvia divinorum use on YouTube. The Journal of Public and Professional Sociology5. Available at: http://digitalcommons.kennesaw.edu/jpps/vol5/iss1/6.
49. Peckys D, Landwehrmeyer GB. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: A 33P in situ hybridization study. Neuroscience. 1999 ; 88: 1093-1135
50. Perron BE, Ahmedani BK, Vaughn MG, et al. Use of Salvia divinorum in a nationally representative sample. Am J Drug Alcohol Abuse. 2012 ; 38: 108-113
51. Pichini S, Abanades S, Farre M, et al. Quantification of the plant-derived hallucinogen salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom. 2005 ; 19: 1649-1656
52. Przekop P, Lee T. Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry. 2009 ; 166: 832
53. Ranganathan M, Schnakenberg A, Skosnik PD, et al. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biol Psychiatry. 2012 ; 72: 871-879
54. Reissig CJ, Carter LP, Johnson MW, et al. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology (Berl). 2012 ; 223: 1-15
55. Riba J, Rodriguez-Fornells A, Urbano G, et al. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl). 2001 ; 154: 85-95
56. Riba J, Romero S, Grasa E, et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl). 2006 ; 186: 93-98
57. Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A. 2002 ; 99: 11934-11939
58. Rockville, MD: SAMHSA ; 2012 :
59. SiebertD (2014) Sage wisdom botanicals. Available at: http://sagewisdombotanicals.com/.
60. Siebert DJ Salvia divinorum J Ethnopharmacol. and salvinorin A: New pharmacologic findings ; 1994: 53-56.
61. Sierra M, Berrios GE. Depersonalization: Neurobiological perspectives. Biol Psychiatry. 1998 ; 44: 898-908
62. Singh P, Pandey A, Aggarwal A. House-to-house survey vs. snowball technique for capturing maternal deaths in India: A search for a cost-effective method. Indian J Med Res. 2007 ; 125: 550-556
63. Stiefel KM, Merrifield A, Holcombe AO. The claustrum's proposed role in consciousness is supported by the effect and target localization of. Salvia divinorum. Front Integr Neurosci. 2014 ; 8: 20
64. Strassman RJ, Qualls CR, Uhlenhuth EH, et al. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994 ; 51: 98-108
65. Sufka KJ, Loria MJ, Lewellyn K, et al. The effect of Salvia divinorum and Mitragyna speciosa extracts, fraction and major constituents on place aversion and place preference in rats. J Ethnopharmacol. 2014 ; 151: 361-364
66. Sumnall HR, Measham F, Brandt SD, et al. Salvia divinorum use and phenomenology: Results from an online survey. J Psychopharmacol. 2011 ; 25: 1496-1507
67. Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2007 ; 189: 565-573
68. Tejeda HA, Shippenberg TS, Henriksson R. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci. 2012 ; 69: 857-896
69. Travis CR, Ray GA, Marlowe KF. A report of nausea and vomiting with discontinuation of chronic use of. Salvia divinorum. Case Report Med. 2012 ; 2012: 543747
70. Vandrey R, Dunn KE, Fry JA, et al. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012 ; 120: 238-241
71. Vohra R, Seefeld A, Cantrell FL, et al. Salvia divinorum: Exposures reported to a statewide poison control system over 10 years. J Emerg Med. 2011 ; 40: 643-650
72. Walker BM, Valdez GR, McLaughlin JP, et al. Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol. 2012 ; 46: 359-370
73. Walsh LD, Moseley GL, Taylor JL, et al. Proprioceptive signals contribute to the sense of body ownership. J Physiol. 2011 ; 589: 3009-3021
74. White KL, Roth BL. Psychotomimetic effects of kappa opioid receptor agonists. Biol Psychiatry. 2012 ; 72: 797-798
75. Wu LT, Woody GE, Yang C, et al. Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil. 2011 ; 2011: 53-68